| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T125 |
0-35 |
Sentence |
denotes |
Point-of-Care Molecular Diagnostics |
| T126 |
36-427 |
Sentence |
denotes |
Low-complexity, rapid (results within 1 hour) molecular diagnostic tests for respiratory viral infections that are CLIA waived (FDA approved for use outside the laboratory by nonlaboratory personnel) include cartridge-based assays on platforms that include the Abbott ID NOW (Abbott Laboratories), BioFire FilmArray (bioMérieux), cobas Liat (Roche Diagnostics), and GeneXpert (Cepheid) (39). |
| T127 |
428-548 |
Sentence |
denotes |
Rapid point-of-care assays for SARS–CoV-2 on instruments such as these will be critical to expand point-of-care testing. |
| T128 |
549-770 |
Sentence |
denotes |
The Xpert Xpress SARS–CoV-2 test (Cepheid) has received an FDA EUA and is performed on the GeneXpert platform, which is already widely used for tuberculosis and HIV testing, especially in low- and middle-income countries. |
| T129 |
771-988 |
Sentence |
denotes |
This capacity might be useful to scale up testing across the world as well as in settings where rapid results at the point of care would enable clinical decisions, although testing throughput may be a limiting factor. |
